AdAlta

Webinars

Updates

Home

Why Invest

Announcements

Lora

upload.jpg

Special report: An institutional investment of up to $3.7m, including up to $3m to be invested by New Life Sciences Capital, provides important strategic flexibility for AdAlta as it looks to grow other aspects of the business.

AdAlta has received an institutional investment of up to $3m from New Life Sciences LLC and $700,000 from Meurs Group

The two investments will allow the company to accelerate the recent SYNBV MoU

An extended final repayment has also been secured on its existing Treasury Corporation of Victoria (TCV) loan facility

Stockhead Reports: AdAlta locks in $3.7m to speed up Phase II clinical trials, near-term partnerships